Predicting Molecular Models: Where Are We Going?

被引：0
|
作者：
Ratta, Raffaele [1 ]
Verzoni, Elena [1 ]
Grassi, Paolo [1 ]
Niger, Monica [1 ]
Procopio, Giuseppe [1 ]
机构：
[1] Fdn IRSCC Ist Nazl Tumori, Med Oncol 1, Genitourinary Unit, I-20133 Milan, Italy
来源：
EBIOMEDICINE | 2015年 / 2卷 / 11期
关键词：
RENAL-CELL CARCINOMA;
D O I：
10.1016/j.ebiom.2015.09.050
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1594 / 1595
页数：2
相关论文
共 39 条
  • [1] Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
    Jang, Albert
    Adler, David M.
    Rauterkus, Grant P.
    Bilen, Mehmet A.
    Barata, Pedro C.
    CANCERS, 2021, 13 (20)
  • [2] Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?
    Goebell, P. J.
    Bedke, J.
    AKTUELLE UROLOGIE, 2015, 46 (06) : 473 - 480
  • [3] Malnutrition in Spine Oncology: Where Are We and What Are We Measuring?
    Ramos, Rafael de la Garza
    Charest-Morin, Raphaele
    Goodwin, C. Rory
    Zuckerman, Scott L.
    Laufer, Ilya
    Dea, Nicolas
    Sahgal, Arjun
    Rhines, Laurence D.
    Gokaslan, Ziya L.
    Bettegowda, Chetan
    Versteeg, Anne L.
    Chen, Hanbo
    Cordula, Netzer
    Sciubba, Daniel M.
    O'Toole, John E.
    Fehlings, Michael G.
    Kumar, Naresh
    Disch, Alexander C.
    Stephens, Byron
    Goldschlager, Tony
    Weber, Michael H.
    Shin, John H.
    AO Spine Knowledge Forum Tumor
    GLOBAL SPINE JOURNAL, 2025, 15 (1_SUPPL) : 29S - 46S
  • [4] Metastasectomy in renal cell carcinoma: where are we now?
    Lloyd, Alexander
    Reeves, Fairleigh
    Abu-Ghanem, Yasmin
    Challacombe, Ben
    CURRENT OPINION IN UROLOGY, 2022, 32 (06) : 627 - 633
  • [5] Partial nephrectomy in Venezuela. Where are we? present considerations
    Polar, Jasson Lavi
    Espinoza, Alessandri R.
    Leon, Randick
    Hernandez, Maria
    Cruz, German
    Leon, Antonio
    ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (06): : 581 - 589
  • [6] Where are we at with DCE-US (dynamic contrast enhancedultrasonography)?
    Lassau, N.
    ONCOLOGIE, 2010, 12 (03) : 197 - 201
  • [7] Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkers
    Crispen, Paul L.
    Boorjian, Stephen A.
    Lohse, Christine M.
    Leibovich, Bradley C.
    Kwon, Eugene D.
    CANCER, 2008, 113 (03) : 450 - 460
  • [8] Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
    Da Costa, Ines Anselmo
    Rausch, Steffen
    Kruck, Stephan
    Todenhoefer, Tilman
    Stenzl, Arnulf
    Bedke, Jens
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 357 - 368
  • [9] Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
    Bedke, Jens
    Stenzl, Arnulf
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (12) : 1399 - 1408
  • [10] Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Chanza, Nieves Martinez
    Tripathi, Abhishek
    Harshman, Lauren C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (05)
1234